Pharma Horizons: the future of cell and gene therapy

As emerging technologies reshape the landscape, the cell and gene therapy sector faces complex challenges from supply chain disruptions and cost pressures to regulatory demands and manufacturing bottlenecks.

Why should you access this report?

Whether you’re developing breakthrough therapies, leading manufacturing strategy or overseeing quality and compliance, this report offers practical, actionable insights you can apply immediately. Learn how key leaders from Spark Therapeutics, SK Pharmateco, Roslin CT and Medipost are solving today’s urgent challenges, and preparing for the future.

You’ll gain:

• Strategic foresight on the direction of the industry
• Expert-led guidance on compliance, CMC and biomanufacturing
• Proven approaches to streamline operations and reduce costs
• Innovation spotlights on technologies reshaping gene and cell therapy
• Insights from real-world leaders tackling regulatory and commercial barriers

Inside this report:

Articles include:

• Recent trends in cell and gene therapy
• Using technology to advance biomanufacturing for cell therapies
• Navigating aseptic validation and innovation in cell and gene therapy
• PAT implementation in cell therapies: a European perspective on cost reduction
• Overcoming mycoplasma testing challenges in cell and gene manufacturing with Biofire® 
• Regenerative medicine – QC and CMC insights
• Delivering enhanced QC and analytical strategies for gene therapies
• Navigating the commercialisation of cell and gene therapies

Download the full report now to discover strategies, tools and innovations that will position your organisation for long-term success.

Unlock the full report and discover more >>

This Pharma Horizons report is brought to you in association with: